Antibody therapy in renal cell carcinoma
Open Access
- 1 February 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in World Journal of Urology
- Vol. 26 (2), 141-146
- https://doi.org/10.1007/s00345-008-0236-5
Abstract
The treatment of metastasized renal cell carcinoma (RCC) still represents a formidable challenge, despite the development of small molecule, tyrosine kinase inhibitors (TKI) that have made a major impact on the disease. Although the percentage of patients achieving a partial response or stabilization of disease has been impressive, these effects are mostly non-durable. Additionally, drug-related side effects can be quite severe. Alternative treatment modalities might be monoclonal antibodies (mAbs). mAbs against RCC-associated antigens have been developed and have shown promise. Additionally, current efforts focus on Bevacizumab that recognizes vascular endothelial growth factor (VEGF). VEGF overexpression in RCC provides the opportunity to inhibit this proangiogenic pathway. Also with Bevacizumab, promising results have been obtained, particularly in combination with other treatment modalities. It is likely that mAbs, either as single agents or in combination with other agents, may become useful additions to the armamentarium to diagnose and treat RCC.Keywords
This publication has 32 references indexed in Scilit:
- A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell CarcinomaJournal of Urology, 2006
- Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and ErlotinibJournal of Clinical Oncology, 2005
- Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinomaOncogene, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated EffectorsJournal of Immunotherapy, 1996
- Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidneyInternational Journal of Cancer, 1986
- Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975